Consistent with this, the application of current clinical guidelines for CA125 to both cohorts results in large numbers of controls falling above the clinical threshold and both ovarian cancer and early-stage ovarian cancer samples falling below the clinical threshold (Fig. 2). The gene discussed is MUC16; the disease is ovarian cancer.